In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences Corp (NASDAQ:EXAS) EVP of Precision Oncology, Brian Baranick, has recently sold a portion of his company stock, according to the latest filings. On September 18, Baranick sold 929 ...

Exact Sciences Corp (NASDAQ:EXAS) EVP of Precision Oncology, Brian Baranick, has recently sold a portion of his company stock, according to the latest filings. On September 18, Baranick sold 929 ...

On Monday, BTIG updated its outlook on Exact Sciences Corp (NASDAQ:EXAS), increasing the price target to $82 from the previous $70 while reiterating a Buy rating on the stock. The adjustment ...

BTIG and Piper Sandler have raised their price targets to $82 and $85 respectively, both maintaining a positive rating on Exact Sciences shares. Citi has reaffirmed its Buy rating and $80.00 stock ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...